KR20030003124A - 파골세포형성 억제인자 및 다당류를 함유하는 복합체 - Google Patents

파골세포형성 억제인자 및 다당류를 함유하는 복합체 Download PDF

Info

Publication number
KR20030003124A
KR20030003124A KR1020020037598A KR20020037598A KR20030003124A KR 20030003124 A KR20030003124 A KR 20030003124A KR 1020020037598 A KR1020020037598 A KR 1020020037598A KR 20020037598 A KR20020037598 A KR 20020037598A KR 20030003124 A KR20030003124 A KR 20030003124A
Authority
KR
South Korea
Prior art keywords
ocif
complex
variants
group
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020020037598A
Other languages
English (en)
Korean (ko)
Inventor
야마모또신이찌
오까다준이찌
구리하라아쯔시
누마자와다꾸
곤도준이찌
쯔다에이스께
모찌즈끼신이찌
니시히로따까
미야자끼히데끼
Original Assignee
상꾜 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상꾜 가부시키가이샤 filed Critical 상꾜 가부시키가이샤
Publication of KR20030003124A publication Critical patent/KR20030003124A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020020037598A 2001-06-29 2002-06-29 파골세포형성 억제인자 및 다당류를 함유하는 복합체 Withdrawn KR20030003124A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPJP-P-2001-00198985 2001-06-29
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
KR20030003124A true KR20030003124A (ko) 2003-01-09

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020020037598A Withdrawn KR20030003124A (ko) 2001-06-29 2002-06-29 파골세포형성 억제인자 및 다당류를 함유하는 복합체

Country Status (22)

Country Link
US (3) US20030045456A1 (enExample)
EP (1) EP1270015A3 (enExample)
KR (1) KR20030003124A (enExample)
CN (1) CN1442201A (enExample)
AR (1) AR034716A1 (enExample)
AU (1) AU783126B2 (enExample)
BR (1) BR0202439A (enExample)
CA (1) CA2392383A1 (enExample)
CO (1) CO5390084A1 (enExample)
CZ (1) CZ20022231A3 (enExample)
HK (1) HK1048762A1 (enExample)
HU (1) HUP0202119A2 (enExample)
IL (1) IL150448A0 (enExample)
MX (1) MXPA02006511A (enExample)
NO (1) NO20023144L (enExample)
PA (1) PA8549401A1 (enExample)
PE (1) PE20030254A1 (enExample)
PL (1) PL354799A1 (enExample)
RU (1) RU2232594C2 (enExample)
SG (1) SG98059A1 (enExample)
SK (1) SK9492002A3 (enExample)
ZA (1) ZA200205164B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
TW529954B (en) 1998-10-28 2003-05-01 Sankyo Co Agent for treating abnormal bone metabolism
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
AU2003208621A1 (en) * 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
EA007927B1 (ru) 2002-04-10 2007-02-27 Апплайд Резеч Системз Арс Холдинг Н. В. Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
RU2323227C2 (ru) * 2003-03-24 2008-04-27 Санкио Компани Лимитед Полимерные модификаторы и фармацевтические композиции
RU2370271C2 (ru) * 2006-11-22 2009-10-20 Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН) Способ обнаружения комплексов между гепаринами и поликатионами
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31725A (en) * 1861-03-19 Improvement in cultivators
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US4207A (en) * 1845-09-27 lewis
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US139325A (en) * 1873-05-27 Improvement in carriage-springs
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
DE69834719D1 (de) * 1997-09-24 2006-07-06 Sankyo Co Methode zur diagnose von abnormalem knochenstoffwechsel
DE69904818T2 (de) * 1998-06-15 2003-10-09 Takeda Chemical Industries, Ltd. Thienodipyridinderivate, ihre herstellung und verwendung
TW529954B (en) * 1998-10-28 2003-05-01 Sankyo Co Agent for treating abnormal bone metabolism
ES2287028T3 (es) * 1999-09-03 2007-12-16 Amgen Inc. Composiciones y metodos para la prevencion o el tratamiento de cancer y de la perdida osea asociada con el cancer.
WO2002026191A2 (en) * 2000-09-28 2002-04-04 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
AU2003208621A1 (en) * 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물

Also Published As

Publication number Publication date
PA8549401A1 (es) 2003-07-28
RU2232594C2 (ru) 2004-07-20
AU783126B2 (en) 2005-09-29
HU0202119D0 (enExample) 2002-08-28
PL354799A1 (en) 2002-12-30
HK1048762A1 (en) 2003-04-17
NO20023144D0 (no) 2002-06-28
NO20023144L (no) 2002-12-30
HUP0202119A2 (hu) 2003-04-28
RU2002117385A (ru) 2004-01-27
IL150448A0 (en) 2002-12-01
US20030045456A1 (en) 2003-03-06
CA2392383A1 (en) 2002-12-29
EP1270015A3 (en) 2004-02-25
CN1442201A (zh) 2003-09-17
CZ20022231A3 (cs) 2003-02-12
EP1270015A2 (en) 2003-01-02
US20030139325A1 (en) 2003-07-24
ZA200205164B (en) 2003-03-24
SK9492002A3 (en) 2003-02-04
CO5390084A1 (es) 2004-04-30
AU5071902A (en) 2003-01-02
BR0202439A (pt) 2003-06-10
PE20030254A1 (es) 2003-03-19
AR034716A1 (es) 2004-03-17
SG98059A1 (en) 2003-08-20
US20060084595A1 (en) 2006-04-20
MXPA02006511A (es) 2004-08-11

Similar Documents

Publication Publication Date Title
JP6976859B2 (ja) ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
EP1121155B1 (en) Site-directed dual pegylation of proteins
JP2006512326A (ja) 心臓疾患におけるエリスロポエチンの新規な使用
US20230000950A1 (en) Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
KR20030003124A (ko) 파골세포형성 억제인자 및 다당류를 함유하는 복합체
JP2025085685A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体の肝疾患に対する治療的使用
EP4197550A1 (en) Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
US20030216297A1 (en) Pharmaceutical composition
AU691085B2 (en) Anti-inflammatory CD14 polypeptides
EP4183407A1 (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
JP2004203747A (ja) 破骨細胞形成抑制因子を含有する治療剤
WO2004083242A1 (en) Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2850091C1 (ru) Терапевтическое применение производного глюкагона или его конъюгата при заболевании печени
CN115916238A (zh) 包含胰高血糖素/GLP-l/GIP受体三重激动剂或其缀合物的高血脂症预防或治疗组合物及其使用方法
KR20220010462A (ko) 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도
JP2004059582A (ja) 骨破壊の治療または予防剤組成物の併用効果
CA2368937A1 (en) Prevention of brain damage in stroke
JP2003321390A (ja) 医薬組成物
JP2003160601A (ja) 破骨細胞形成抑制因子を含有する複合体
CN118891057A (zh) 肝脏靶向物质及其用途
US20250121086A1 (en) Liver-targeted substance and use thereof
HK40075122A (en) Glucagon, composition comprising glp-1 receptor and gip receptor dual agonist and therapeutic use thereof
MXPA01003764A (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20020629

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid